



RESEARCH NOTE

REVISED Seasonality of birth defects in West Africa: could congenital Zika syndrome be to blame? [version 2; referees: 2 approved, 1 approved with reservations]

Maimuna S. Majumder^{1,2}, Rosanna Hess³, Ratchneewan Ross⁴, Helen Piontkivska ⁵

¹Computational Epidemiology Group, Division of Emergency Medicine, Boston Children's Hospital, Boston, MA, 02115, USA

²Engineering Systems Division, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA

³Research for Health, Inc., Cuyahoga Falls, OH, 44223, USA

⁴School of Nursing, University of North Carolina at Greensboro, Greensboro, NC, 27408, USA

⁵241 Cunningham Hall, Department of Biological Sciences & School of Biomedical Sciences, Kent State University, Kent, OH, 44242, USA


v2 First published: 07 Feb 2018, 7:159 (doi: [10.12688/f1000research.13858.1](https://doi.org/10.12688/f1000research.13858.1))
 Latest published: 19 Jul 2018, 7:159 (doi: [10.12688/f1000research.13858.2](https://doi.org/10.12688/f1000research.13858.2))

Abstract

The link between Zika virus infection during pregnancy and microcephaly and other neurodevelopmental defects in infants, referred to as congenital Zika syndrome (CZS), was recently discovered. One key question that remains is whether such neurodevelopmental abnormalities are limited to the recently evolved Asiatic ZIKV strains or if they can also be induced by endemic African strains. Thus, we examined birth registries from one particular hospital from a country in West Africa, where ZIKV is endemic. Results showed a seasonal pattern of birth defects that is consistent with potential CZS, which corresponds to a range of presumed maternal infection that encompasses both the peak of the warm, rainy season as well as the months immediately following it, when mosquito activity is likely high. While we refrain from definitively linking ZIKV infection and birth defects in West Africa at this time, in part due to scant data available from the region, we hope that this report will initiate broader surveillance efforts that may help shed light onto mechanisms underlying CZS.

Keywords

Zika virus; ZIKV; birth defects; microcephaly; congenital Zika syndrome; West Africa; seasonality



This article is included in the [Disease Outbreaks gateway](#).

Open Peer Review

Referee Status:

| | Invited Referees | | |
|--------------------------|------------------|--------|--------|
| | 1 | 2 | 3 |
| REVISED | | | |
| version 2 | report | report | |
| published 19 Jul 2018 | | | |
| version 1 | | | |
| published 07 Feb 2018 | report | report | report |

- 1 **Matthew T. Aliota** , University of Minnesota, USA
- 2 **Diana Valencia**, Centers for Disease Control and Prevention (CDC), USA
- 3 **Catherine M. Brown**, Massachusetts Department of Public Health (MDPH), USA

Discuss this article

Comments (0)

Corresponding author: Helen Piontkivska (opiontki@kent.edu)

Author roles: **Majumder MS:** Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Hess R:** Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing; **Ross R:** Conceptualization, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; **Piontkivska H:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was partially supported by the Research Seed Award from Kent State University (to HP) and by Research For Health, Inc. (to RH).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Majumder MS *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Majumder MS, Hess R, Ross R and Piontkivska H. **Seasonality of birth defects in West Africa: could congenital Zika syndrome be to blame? [version 2; referees: 2 approved, 1 approved with reservations]** *F1000Research* 2018, 7:159 (doi: [10.12688/f1000research.13858.2](https://doi.org/10.12688/f1000research.13858.2))

First published: 07 Feb 2018, 7:159 (doi: [10.12688/f1000research.13858.1](https://doi.org/10.12688/f1000research.13858.1))

REVISED Amendments from Version 1

In this revision, we have clarified some characteristics of the hospital from which the birth registry data were obtained, including the requirement that the name of the hospital and the country be withheld as a condition of accessing the data. We added the emphasis to the statement about surveillance needs, in particular, that these should encompass both the infectious agents surveillance as well as birth defects surveillance. We also updated the [Figure 1](#) and its legend for more clear presentation, and have added references to seroprevalence studies of ZIKV in West Africa.

See referee reports

Introduction

Since 2015, when an initial link between Zika Virus (ZIKV) and microcephaly was discovered in Brazil^{1,2}, the term congenital Zika syndrome (CZS) has been coined to reflect a broad range of Zika-linked neurodevelopmental damages³ beyond microcephaly³⁻⁵, including ocular^{6,7} and auditory defects^{8,9}. The overall risk of Zika-linked birth defects has been estimated at ~10% and 15% for infections during the 1st trimester¹⁰, potentially impacting thousands of infants in the US and US territories alone. Concerns exist that ZIKV-related outcomes are underreported, particularly when ZIKV infections result in neurodevelopmental abnormalities without visible microcephaly (e.g., developmental delays and learning disabilities that would not be immediately noticeable¹¹⁻¹³). Such outcomes are likely not recorded, particularly if the causative infection was asymptomatic¹⁴. Further, a recent CDC report that examined birth defect records from 15 US jurisdictions showed a statistically significant increase in prevalence of birth defects potentially consistent with CZS in areas with documented local ZIKV transmission in the second half of 2016¹⁵. Notably, the majority of infants and fetuses with birth defects potentially related to ZIKV infection in this report lacked ZIKV infection testing, which may be in part attributed to lack of known maternal exposure or other such indicators¹⁶. Nonetheless, these findings are alarming and underscore not only the need for continued monitoring and surveillance, but also the need to better understand the full extent – as well as mechanisms – of neurodevelopmental defects associated with CZS.

Can we expect to find cases of congenital Zika syndrome in the African Continent?

Currently our understanding of the mechanisms that underlie CZS remains limited, including the possibility that ZIKV infection is a necessary but insufficient condition for CZS¹⁷. One key question is whether ZIKV-mediated birth defects are associated with a specific strain of ZIKV, which, for example, could have evolved after ZIKV migrated from South East Asia to French Polynesia and Brazil¹⁸ and now spread to North America, including the US^{10,15}. However, other studies suggest that African strains are likely to be as pathogenic as the Asiatic strains (e.g., [19](#), [20](#)). Thus, the lack of connection between ZIKV infection in pregnancy and birth defects prior to the 2015–16 Brazilian outbreak may instead be attributable to the benign nature of ZIKV infection in adults²¹ and lack of surveillance, including that infectious agents as well as surveillance of birth defects, among other factors. This can be illustrated by a report

of a handful of birth defects in Hawaii in 2009–2012, which now has been shown to be associated with ZIKV infection, but was undetected as such until the Brazilian microcephaly epidemic brought ZIKV into the spotlight²².

Earlier studies from the African Continent – where ZIKV is endemic – have documented a relatively high prevalence of ZIKV antibodies in human populations, including in West Africa (e.g., Nigeria^{23,24}, Sierra-Leone²⁵, Senegal²⁶, Burkina Faso, Cote D'Ivoire, Guinea-Bissau, Cameroon, Mali, Niger, Benin, Gabon²⁷, supporting the premise that ZIKV is present across multiple countries in West Africa region (reviewed in Kindhauser *et al.*²⁸). Despite this, there exists negligible data regarding CZS across the African Continent; nevertheless, lack of evidence should not be taken as definitive proof of absence¹⁹. Thus, here we examine birth registries from one particular hospital in West Africa from a country considered by the WHO to be at medium risk of a ZIKV outbreak²⁹. The study was approved by the Committee on Administration of the hospital where the data was collected in lieu of a functioning Ethics Committee. But as there are ongoing security concerns in this location, that committee required that the hospital name and location be kept anonymous to ensure the safety of the hospital and staff. The chosen hospital has a full service maternity/OB department, staffed by well-trained qualified obstetricians, midwives, and obstetric nurses. It handled about 2000 births per year during the studied period; reports compiled from the hospital data are routinely used by the country's government.

Case study: seasonality of CZS-type birth defects in a hospital in West Africa

Risk of major neurodevelopmental defects, such as microcephaly, appears to be particularly high if vertical transmission occurs during the first trimester, especially within a “vulnerability window” around 12 weeks (10 to 14 weeks) post-conception^{10,30}. Thus, we hypothesized that – similar to seasonal malaria infections, which peak a few weeks following abundant rainfalls during the “rainy” season, typically from August through October in the study region^{31,32} – seasonal variations in the number of CZS-type birth defects would be detectable from the aforementioned hospital data. Such expectations are consistent with prior findings from Senegal (West Africa)³³ and Kenya (East Africa)³⁴, where Rift Valley Fever epizootics were associated with heavy rainfalls. Our hypothesis was further informed by the temporal relationships between the number of ZIKV infections and microcephaly cases reported in Brazil³⁵. We expected that the peak of CZS-type birth defects (such as documented cases of microcephaly and/or stillbirth) would coincide with vertical ZIKV transmission at around 12-weeks post-conception during the peak of the rainy season, assuming an approximate 3-week lag between maternal infection and vertical transmission³⁶, as suggested by data from Brazil in 2015³⁷.

Methods

A total of 13445 birth registries (2009–2015) from a non-governmental hospital in West Africa were examined to determine whether we could identify a seasonal pattern of birth defects potentially attributable to ZIKV infection (i.e., CZS-type birth defects). The number of births and respective outcomes

(i.e., live birth versus stillbirth) and reported complications (i.e., fetal malformation, breech, etc.) were collated by month/year. Reporting standards for birth complications varied between years; thus, we focused exclusively on visible neurodevelopmental complications (such as microcephaly) and pregnancy losses (such as stillbirth) that could be attributed to potential CZS^{3,4} (Supplementary Table 1 and Supplementary Table 2). To infer the “vulnerability window” of 12 weeks (spanning 10 to 14 weeks) post-conception, we assumed that births that were not reported as premature in the records were full-term, thus enabling us to infer the likely month of conception³⁵.

We also considered national average monthly temperature and rainfall data for the study years, collected from the World Bank Climate Change Knowledge Portal database. These values were treated as proxy indicators for mosquito activity in the hospital catchment area at time of maternal infection. To visualize any relevant trends, we plotted these data, as well as the average percentage of birth defects consistent with potential CZS by month.

Results and discussion

As shown in Figure 1, the average percentage of births consistent with potential CZS demonstrates a marked peak between March and July, which places maternal month of infection between August and December of the previous year. These months encompass the peak and latter half of the warm, rainy season (August–October) as well as the first half of the cool, dry season that immediately follows (October–December) in the study region, which likely represents months with considerable mosquito activity. Notably, the hospital from which these birth defects data were acquired also generally experiences a peak in childhood malaria cases every October, which falls squarely in the middle of the August to December range of presumed maternal month of ZIKV infection determined here.

With this in mind, the early months of the cool, dry season (October–December) are likely hospitable enough for mosquito vectors to thrive and spread pathogens, including ZIKV; this may explain why the range of our presumed maternal month of infection (August–December) extends past the rainy season,




Figure 1. Average birth defects consistent with congenital Zika syndrome per month, with corresponding average daily temperatures and rainfall during presumed maternal month of infection. Bottom axis corresponds with the birth month depicted with yellow bars (i.e., with the left scale that shows % CZS defects), while the top axis corresponds with the month of maternal infection (and thus, with the rainfall and temperature shown on the left, depicted in green and red, respectively).

given that mosquitoes require a balanced environment for survival, including both moderate rainfall and optimal temperatures³⁸.

Our results suggest that a seasonal pattern exists with respect to CZS-type birth defects reported in the study region (Figure 1), where the largest fraction of said defects appear to occur in the months of March through July. Furthermore, this pattern can be linked to ecological evidence, such as rainfall and temperature trends that likely facilitate maternal ZIKV infection. While consistent with the expectation that some of these defects might be attributable to (unreported) ZIKV infections that occurred early in pregnancy (and indeed resemble temporal patterns from studies in Brazil³⁵), our findings stop short of definitively linking ZIKV infection and birth defects in the study region, in part due to scant data. Instead, by reviewing the potential limitations of the data analyzed here, we hope that this report will initiate broader surveillance efforts – of both the infectious agents, including ZIKV, as well as that of birth defects – that may help shed light onto mechanisms that underlie CZS, including utilization of data that might already be available across various African countries where ZIKV is endemic and/or competent vectors exist (e.g., Gabon³⁹, Central African Republic⁴⁰). For example, a recent WHO Bulletin on Outbreaks and Other Emergencies⁴¹ reported a number of microcephaly cases from Angola (a country listed in the High risk category²⁹) that appear to be linked to ZIKV infection, despite the lack of direct PCR confirmation from the specimens. Due to only recent implementation of active surveillance in the country, the true magnitude of the event is not yet clearly understood. Nonetheless, it is important for insights into a broader pattern of potential CZS defects, despite the lack of experimental ZIKV infection confirmation or lack of evidence of ongoing active ZIKV transmission in Angola (i.e. only two ZIKV cases were reported from Angola in early 2017⁴²).

Several conservative assumptions made in this analysis, such as assuming a gestation period of ~9 months, or not classifying “low birth weights” (which may represent full-term births of ZIKV-infected fetuses) as a CZS-type birth defect, would likely lead to underestimation of potential trends, if any. We also assumed that the available birth records were representative of the pregnancy/birth patterns that occur across the entire region. Other limitations of the available data are related to the standard of care that is feasible in much of West Africa, including (i) lack of family history and/or genetic testing for mutations in loci responsible for primary microcephaly; (ii) lack of laboratory

evidence or testing for ZIKV and/or other infections, including TORCH agents^{43,44}, often due to inability to pay for testing (e.g., 45); and (iii) lack of detailed clinical prenatal history, including whether rash and/or other symptoms of Zika infection were present at any point during pregnancy. This final limitation may be considered minor, given that the majority of ZIKV infections are asymptomatic^{21,30}. Additionally, no data were available regarding other clinically relevant factors that are also associated with microcephaly⁴⁶, such as history of excessive alcohol consumption or recreational drug use, and/or prolonged exposure to pesticides, such as pyriproxyfen. However, the former life-style factors are unlikely to have a seasonal effect spanning several years, and the role of the latter factor as a causative agent of microcephaly remains unclear⁴⁷. There is also a lack of precise ecological data, including estimates of rainfalls in the hospital catchment area, the distribution and feeding habits of mosquitoes, and whether or not said mosquitoes carry ZIKV, as well as data regarding ZIKV prevalence in the human population.

Despite these limitations, our findings suggest that using the data we already have – even in the absence of formal surveillance systems for CZS – can provide compelling, introductory insights. In the future, work that employs existing data from hospitals across the African continent – which encompasses countries with a variety of climates, dry and rainy seasons, and suitability for widespread mosquito habitats – should be pursued.

Data availability

Figshare : Data for Figure 1. Average birth defects consistent with congenital Zika syndrome per month, with corresponding average daily temperatures and rainfall during presumed maternal month of infection. doi: [10.6084/m9.figshare.5387029](https://doi.org/10.6084/m9.figshare.5387029). Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/) (CC-BY 4.0).

Competing interests

No competing interests were disclosed.

Grant information

This work was partially supported by the Research Seed Award from Kent State University (to HP) and by Research For Health, Inc. (to RH).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary material

Supplemental Table 1. A list of birth complications (as recorded in the health records) consistent with potential congenital Zika syndrome.

[Click here to access the data.](#)

Supplemental Table 2. A list of birth complications (as recorded in the health records) that are not consistent with potential congenital Zika syndrome and/or missing.

[Click here to access the data.](#)

References

1. Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, *et al.*: **Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy - Brazil, 2015.** *MMWR Morb Mortal Wkly Rep.* 2016; **65**(9): 242–247. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Rasmussen SA, Jamieson DJ, Honein MA, *et al.*: **Zika Virus and Birth Defects—Reviewing the Evidence for Causality.** *N Engl J Med.* 2016; **374**(20): 1981–1987. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Melo AS, Aguiar RS, Amorim MM, *et al.*: **Congenital Zika Virus Infection: Beyond Neonatal Microcephaly.** *JAMA Neurol.* 2016; **73**(12): 1407–1416. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Lucey D, Cummins H, Sholtis S: **Congenital Zika Syndrome in 2017.** *JAMA.* 2017; **317**(13): 1368–1369. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Moore CA, Staples JE, Dobyns WB, *et al.*: **Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians.** *JAMA Pediatr.* 2017; **171**(3): 288–295. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Singh PK, Guest JM, Kanwar M, *et al.*: **Zika virus infects cells lining the blood-retinal barrier and causes chorioretinal atrophy in mouse eyes.** *JCI Insight.* 2017; **2**(4): e92340. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Culjat M, Darling SE, Nerurkar VR, *et al.*: **Clinical and Imaging Findings in an Infant With Zika Embryopathy.** *Clin Infect Dis.* 2016; **63**(6): 805–811. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Glantz G: **Zika and Hearing Loss: The Race for a Cure Continues.** *Hear J.* 2016; **69**(12): 22–24. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Leal MC, Muniz LF, Ferreira TS, *et al.*: **Hearing Loss in Infants with Microcephaly and Evidence of Congenital Zika Virus Infection - Brazil, November 2015–May 2016.** *MMWR Morb Mortal Wkly Rep.* 2016; **65**(34): 917–919. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Reynolds MR, Jones AM, Petersen EE, *et al.*: **Vital Signs: Update on Zika Virus-Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure - U.S. Zika Pregnancy Registry, 2016.** *MMWR Morb Mortal Wkly Rep.* 2017; **66**(13): 366–373. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Vogel G: **INFECTIOUS DISEASE. Experts fear Zika's effects may be even worse than thought.** *Science.* 2016; **352**(6292): 1375–1376. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Hotez PJ: **What Does Zika Virus Mean for the Children of the Americas?** *JAMA Pediatr.* 2016; **170**(8): 787–789. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Soares de Souza A, Moraes Dias C, Braga FD, *et al.*: **Fetal Infection by Zika Virus in the Third Trimester: Report of 2 Cases.** *Clin Infect Dis.* 2016; **63**(12): 1622–1625. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Hotez P, Aksoy S: **Will Zika become the 2016 NTD of the Year?** Blog, posted January 7, 2016 by Peter Hotez and Serap Aksoy. 2016. [Reference Source](#)
15. Delaney A, Mai C, Smoots A, *et al.*: **Population-Based Surveillance of Birth Defects Potentially Related to Zika Virus Infection - 15 States and U.S. Territories, 2016.** *MMWR Morb Mortal Wkly Rep.* 2018; **67**(3): 91–96. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Fitzgerald B, Boyle C, Honein MA: **Birth Defects Potentially Related to Zika Virus Infection During Pregnancy in the United States.** *JAMA.* 2018; **319**(12): 1195–1196. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. de Oliveira WK, Carmo EH, Henriques CM, *et al.*: **Zika Virus Infection and Associated Neurologic Disorders in Brazil.** *N Engl J Med.* 2017; **376**(16): 1591–1593. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Faria NR, Quick J, Claro IM, *et al.*: **Establishment and cryptic transmission of Zika virus in Brazil and the Americas.** *Nature.* 2017; **546**(7658): 406–410. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Nutt C, Adams P: **Zika in Africa: the invisible epidemic?** *Lancet.* 2017; **389**(10079): 1595–1596. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Zhu Z, Chan JF, Tee KM, *et al.*: **Comparative genomic analysis of pre-epidemic and epidemic Zika virus strains for virological factors potentially associated with the rapidly expanding epidemic.** *Emerg Microbes Infect.* 2016; **5**: e22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Duffy MR, Chen TH, Hancock WT, *et al.*: **Zika virus outbreak on Yap Island, Federated States of Micronesia.** *N Engl J Med.* 2009; **360**(24): 2536–2543. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Kumar M, Ching L, Astern J, *et al.*: **Prevalence of Antibodies to Zika Virus in Mothers from Hawaii Who Delivered Babies with and without Microcephaly between 2009–2012.** *PLoS Negl Trop Dis.* 2016; **10**(12): e0005262. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Fagbami AH: **Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State.** *J Hyg (Lond).* 1979; **83**(2): 213–219. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Adekolu-John EO, Fagbami AH: **Arthropod-borne virus antibodies in sera of residents of Kainji Lake Basin, Nigeria 1980.** *Trans R Soc Trop Med Hyg.* 1983; **77**(2): 149–151. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Robin Y, Mouchet J: **[Serological and entomological study on yellow fever in Sierra Leone].** *Bull Soc Pathol Exot Filiales.* 1975; **68**(3): 249–258. [PubMed Abstract](#)
26. Renaudet J, Jan C, Ridet J, *et al.*: **[A serological survey of arboviruses in the human population of Senegal].** *Bull Soc Pathol Exot Filiales.* 1978; **71**(2): 131–140. [PubMed Abstract](#)
27. Brès P: **[Recent data from serological surveys on the prevalence of arbovirus infections in Africa, with special reference to yellow fever].** *Bull World Health Organ.* 1970; **43**(2): 223–267. [PubMed Abstract](#) | [Free Full Text](#)
28. Kindhauser MK, Allen T, Frank V, *et al.*: **Zika: the origin and spread of a mosquito-borne virus.** *Bull World Health Organ.* 2016; **94**(9): 675–686C. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. WHO, World Health Organization: **Zika Virus risk assessment in the WHO African Region: a technical report.** February 2016. 2016. [Reference Source](#)
30. Honein MA, Dawson AL, Petersen EE, *et al.*: **Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy.** *JAMA.* 2017; **317**(1): 59–68. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Brewster DR, Greenwood BM: **Seasonal variation of paediatric diseases in The Gambia, west Africa.** *Ann Trop Paediatr.* 1993; **13**(2): 133–146. [PubMed Abstract](#) | [Publisher Full Text](#)
32. Sivakumar MVK: **Predicting rainy season potential from the onset of rains in Southern Sahelian and Sudanian climatic zones of West Africa.** *Agr Forest Meteorol.* 1988; **42**(4): 295–305. [Publisher Full Text](#)
33. Wilson ML, Chapman LE, Hall DB, *et al.*: **Rift Valley fever in rural northern Senegal: human risk factors and potential vectors.** *Am J Trop Med Hyg.* 1994; **50**(6): 663–675. [PubMed Abstract](#) | [Publisher Full Text](#)
34. Davies FG, Linthicum KJ, James AD: **Rainfall and epizootic Rift Valley fever.** *Bull World Health Organ.* 1985; **63**(5): 941–943. [PubMed Abstract](#) | [Free Full Text](#)
35. Reefhuis J, Gilboa SM, Johansson MA, *et al.*: **Projecting Month of Birth for At-Risk Infants after Zika Virus Disease Outbreaks.** *Emerg Infect Dis.* 2016; **22**(5): 828–832. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Lessler J, Chaisson LH, Kucirka LM, *et al.*: **Assessing the global threat from Zika virus.** *Science.* 2016; **353**(6300): aaf8160. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Zhang Q, Sun K, Chinazzi M, *et al.*: **Spread of Zika virus in the Americas.** *Proc Natl Acad Sci U S A.* 2017; **114**(22): E4334–E4343. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Blanford JI, Blanford S, Crane RG, *et al.*: **Implications of temperature variation for malaria parasite development across Africa.** *Sci Rep.* 2013; **3**: 1300. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Grard G, Caron M, Mombo IM, *et al.*: **Zika virus in Gabon (Central Africa)—2007: a new threat from *Aedes albopictus*?** *PLoS Negl Trop Dis.* 2014; **8**(2): e2681. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Berthet N, Nakouné E, Kamgang B, *et al.*: **Molecular characterization of three Zika flaviviruses obtained from sylvatic mosquitoes in the Central African Republic.** *Vector Borne Zoonotic Dis.* 2014; **14**(12): 862–865. [PubMed Abstract](#) | [Publisher Full Text](#)
41. WHO: **Weekly Bulletin on Outbreaks and Other Emergencies, Week 48: 25 November – 1 December 2017.** 2017. [Reference Source](#)
42. WHO: **Zika situation report.** 20 January 2017. 2017. [Reference Source](#)
43. Coyne CB, Lazear HM: **Zika virus - reigniting the TORCH.** *Nat Rev Microbiol.* 2016; **14**(11): 707–715. [PubMed Abstract](#) | [Publisher Full Text](#)
44. Vouga M, Baud D: **Imaging of congenital Zika virus infection: the route to identification of prognostic factors.** *Prenat Diagn.* 2016; **36**(9): 799–811. [PubMed Abstract](#) | [Publisher Full Text](#)
45. Eballé AO, Ellong A, Koki G, *et al.*: **Eye malformations in Cameroonian children: a clinical survey.** *Clin Ophthalmol.* 2012; **6**: 1607–1611. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Calvet G, Aguiar RS, Melo ASO, *et al.*: **Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study.** *Lancet Infect Dis.* 2016; **16**(6): 653–660. [PubMed Abstract](#) | [Publisher Full Text](#)
47. Bar-Yam Y, Nijhout HF, Parens R, *et al.*: **The Case for Pyriproxyfen as a Potential Cause for Microcephaly; From Biology to Epidemiology.** arXiv preprint arXiv: 170303765. 2017. [Publisher Full Text](#)

Open Peer Review

Current Referee Status:   

Version 2

Referee Report 03 August 2018

doi:[10.5256/f1000research.17079.r36769](https://doi.org/10.5256/f1000research.17079.r36769)



Matthew T. Aliota 

University of Minnesota, Minneapolis, MN, USA

The authors have addressed my concerns adequately.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 23 July 2018

doi:[10.5256/f1000research.17079.r36262](https://doi.org/10.5256/f1000research.17079.r36262)



Diana Valencia

Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

The authors addressed all my concerns, and have no further comments.

Competing Interests: No competing interests were disclosed.

Referee Expertise: Birth defects surveillance in low and middle income countries

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Referee Report 25 June 2018

doi:[10.5256/f1000research.15063.r35015](https://doi.org/10.5256/f1000research.15063.r35015)



Catherine M. Brown

Massachusetts Department of Public Health (MDPH), Boston, MA, USA

The authors present an analysis of birth defects by season from a single hospital in an unnamed West African country relative to a purported mosquito season. Their conclusion is that the seasonality of certain types of birth defects, consistent with CZS, could be explained by Zika virus transmission in the area. This is an interesting attempt to use available data to speculate about the impact of Zika virus on congenital defects in an endemic area. Although this is certainly thought-provoking and supports the authors' recommendation to improve surveillance for Zika virus in endemic areas, there is insufficient discussion of all of the limitations to this particular analysis which, if included, would cast doubt on their proposed conclusion.

The limitation that the data are from a single hospital in an un-named location make it impossible to make any generalizable conclusions and to understand any limitations completely.

Data do not exist on the underlying sero-prevalence of Zika virus infection in this population (I assume). However, given that Zika virus infection likely results in lifelong immunity, one might not expect to see any change in CZS-like defects simply due to a low number of susceptible pregnant women. Were the women with infants with birth defects generally younger and therefore less likely to have been previously infected? And why wouldn't we expect children to have a high rate of infection resulting in immunity as they reach child-bearing age?

Again, although difficult to determine given the lack of geographic specificity provided, there is minimal discussion in the paper of other potential causes of microcephaly; most notably rubella and malnutrition. Although rubella-related birth defects might not be expected to show any seasonality, malnutrition might. As might toxoplasmosis.

The time period covered by this report encompasses both the Ebola outbreak and significant Yellow fever activity; both of these could cause confounding in the data.

Mosquito species are quite variable in their feeding habits, optimal climactic conditions and in their vectorial capacity. Relying on patterns of malarial disease to represent what is likely to happen with a flavivirus like Zika which is transmitted by different species of mosquitoes should be considered to be a limitation. What about using Yellow fever or dengue disease patterns?

Lastly, while I understand the argument the authors are making, I found the assertion that the maternal infection period of August through October encompassed the peak and latter half of the warm, rainy season confusing. Based on the presented data, August through October had minimal rain and lower than average temperatures. October through December was described as the cool, dry season although temperatures peak for the year in November through January (according to the data presented by the authors).

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Jul 2018

Helen Piontkivska, Kent State University

>>>The limitation that the data are from a single hospital in an un-named location make it impossible to make any generalizable conclusions and to understand any limitations completely.

We appreciate these limitations, and they were requirements for us to access the data. Specifically, the Committee on Administration of the hospital required us not to name the hospital or the country. We added a statement clarifying this. Our goal was to spur further discussion and further research from larger sample sizes in multiple locations in order to access the generality of this pattern.

>>> Data do not exist on the underlying sero-prevalence of Zika virus infection in this population (I assume). However, given that Zika virus infection likely results in lifelong immunity, one might not expect to see any change in CZS-like defects simply due to a low number of susceptible pregnant women. Were the women with infants with birth defects generally younger and therefore less likely to have been previously infected? And why wouldn't we expect children to have a high rate of infection resulting in immunity as they reach child-bearing age?

It is still unclear whether in humans (versus non-human primates) Zika infection confers life-long immunity (Siedner, Ryan and Bogoch 2018). However, age distribution of mothers of infants with CZS-like birth defects indicates that such birth defects appear across multiple age cohorts, from 15 to 37, with the mean number of CZS-like cases per each age group of 2.39 (\pm standard error of 0.42). Further research of larger cohorts across different locations is needed to definitively test whether there are any maternal-age related effects.

>>> Again, although difficult to determine given the lack of geographic specificity provided, there is minimal discussion in the paper of other potential causes of microcephaly; most notably rubella and malnutrition. Although rubella-related birth defects might not be expected to show any seasonality, malnutrition might. As might toxoplasmosis. The time period covered by this report encompasses both the Ebola outbreak and significant Yellow fever activity; both of these could cause confounding in the data.

We agree that there are many human health issues that could display seasonality. This underscores the need for widespread comprehensive test for infectious agents and prenatal care,

although implementation of such tests in Africa will require significant investments to be feasible.

>>> *Mosquito species are quite variable in their feeding habits, optimal climactic conditions and in their vectorial capacity. Relying on patterns of malarial disease to represent what is likely to happen with a flavivirus like Zika which is transmitted by different species of mosquitoes should be considered to be a limitation. What about using Yellow fever or dengue disease patterns?*

In our inferences we did not rely on the malaria pattern to infer seasonality; instead, it was referenced to indicate consistency in the inferred activities from the temperature and rainfall data. Regretfully, no data regarding yellow fever or dengue infections were available. However, the temperature ranges of the peak transmission of malaria and dengue are overlapping [mid 20's °C for malaria, per (Beck-Johnson et al. 2013); 23-34°C for DENV, per (Mordecai et al. 2017)]. Therefore, we expect that the transmission patterns would be similar.

Beck-Johnson, L. M., et al. (2013). "The effect of temperature on Anopheles mosquito population dynamics and the potential for malaria transmission." *PLoS One* **8**(11): e79276.

Mordecai, E. A., et al. (2017). "Detecting the impact of temperature on transmission of Zika, dengue, and chikungunya using mechanistic models." *PLoS Negl Trop Dis* **11**(4): e0005568.

>>> *Lastly, while I understand the argument the authors are making, I found the assertion that the maternal infection period of August through October encompassed the peak and latter half of the warm, rainy season confusing. Based on the presented data, August through October had minimal rain and lower than average temperatures. October through December was described as the cool, dry season although temperatures peak for the year in November through January (according to the data presented by the authors).*

We revised the figure 1 legend to make it clear that the bottom axis corresponds with the birth month (depicted with yellow bars) and therefore with the left Y axis that shows % CZS-type birth defects, while the top axis corresponds with the month of maternal infection (i.e., with the rainfall and temperature shown on the left, depicted in green and red, respectively). We have also added color guides to the figure to make it visually clear.

Competing Interests: No competing interests were disclosed.

Referee Report 25 June 2018

doi:10.5256/f1000research.15063.r35010



Diana Valencia

Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

Thank you for the opportunity to review this article. I have the following questions/suggestions for the consideration of the authors:

1. The following important reference is missing from the article, please include: Rasmussen et al. (2016)¹
2. Authors should mention that Zika migrated not only to Brazil but to the Americas.

3. What are the characteristics of the chosen hospital? Why only one hospital was chosen? Does the hospital has a good reliable birth defect registry?
4. There is no description of the birth defects taken into account for the paper; which CZS-type birth defects were chosen from the hospital registry? Were the birth defects confirmed? Was any description available in medical records? Were X-rays available for review?
5. I agree with the authors on the importance to have birth defects surveillance systems in place. I hope that this article will contribute to the awareness of public health authorities regarding this important issue.
6. Birth defects surveillance is needed to identify Zika related defects. As the authors mention, the majority of infected pregnant women are asymptomatic.
7. I think it will be important to differentiate in the article between Zika virus surveillance and birth defects surveillance, and the difficulties of implementing them in Africa.

References

1. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR: Zika Virus and Birth Defects--Reviewing the Evidence for Causality. *N Engl J Med*. 2016; **374** (20): 1981-7 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

No

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Referee Expertise: Birth defects surveillance in low and middle income countries

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Jul 2018

Helen Piontkivska, Kent State University

>>> 1. *The following important reference is missing from the article, please include: Rasmussen et al. (2016)*

Thank you for pointing out our oversight. We added this important reference to the paper.

>>>> 2. *Authors should mention that Zika migrated not only to Brazil but to the Americas.*

Done.

>>>> 3. *What are the characteristics of the chosen hospital? Why only one hospital was chosen? Does the hospital has a good reliable birth defect registry?*

Additional identifiable characteristics were not included in order to protect the identity of the hospital; however, we now added several broad characteristics of the hospital to the manuscript. These were the only data that were available to us, and we are confident in the quality of the birth defect registry. We are excited that we were able to demonstrate this trend even with the relatively small sample available to us. We hope this study will spur further comprehensive analyses of larger datasets.

>>> 4. *There is no description of the birth defects taken into account for the paper; which CZS-type birth defects were chosen from the hospital registry? Were the birth defects confirmed? Was any description available in medical records? Were X-rays available for review?*

The description of birth complications that we categorize as a CZS-type (i.e., birth defects consistent with potential congenital Zika syndrome) are listed in the Supplementary table 1, while Supplementary table 2 lists the non-CZS-type complications. We did not have access to individuals' medical records beyond the descriptions listed in Supplementary tables. The hospital does not routinely perform X-rays on newborns with birth defects; thus, no further description of cases or X-rays were available to us.

>>> 5. *I agree with the authors on the importance to have birth defects surveillance systems in place. I hope that this article will contribute to the awareness of public health authorities regarding this important issue.*

6. *Birth defects surveillance is needed to identify Zika related defects. As the authors mention, the majority of infected pregnant women are asymptomatic.*

Thank you, we completely agree.

>>> 7. *I think it will be important to differentiate in the article between Zika virus surveillance and birth defects surveillance, and the difficulties of implementing them in Africa.*

We agree, and have added statements to that effect. Enhanced birth defect surveillance within hospitals are potentially feasible with the current resources, although they may require additional personnel and/or training. However, the surveillance of birth defects outside of hospital settings would be problematic, though potentially possible. On the other hand, Zika virus surveillance per se, as well as surveillance of other viral diseases, would require substantial financial investments

globally, as well as overcoming other challenges related to the implementation of such surveillance.

Competing Interests: No competing interests were disclosed.

Referee Report 03 April 2018

doi:10.5256/f1000research.15063.r32204



Matthew T. Aliota 

University of Minnesota, Minneapolis, MN, USA

The authors have produced a paper speculating that African lineage Zika virus has the same capacity to cause congenital Zika syndrome (CZS) as more recent Asian/American outbreak isolates. This was accomplished by analyzing birth outcome reports from one hospital in West Africa and temporally linking outcomes consistent with CZS to seasonal patterns when mosquito populations would be abundant. The paper is well written and certainly addresses an outstanding question in the field. In sum, this article's major purpose is to create a discussion and provide a rationale for broader Zika surveillance activities in Africa, which I believe has been accomplished, however, there are a few minor details that could be changed to facilitate understanding by the reader.

1. I understand the need for security and thus not naming the hospital but would naming the country truly jeopardize security?
2. While I agree that it is possible that African ZIKV has always had the capability of causing CZS and that it is likely underreported or unrecognized, an alternative explanation is that in Africa where ZIKV is endemic girls and women are exposed early in life and subsequent immunity provides protection against CZS during child bearing years. Is there any age distribution that can be associated with the outcomes presented here?
3. Throughout comparisons are made to Malaria which is transmitted by Anopheles mosquitoes, whereas, ZIKV is likely transmitted by an Aedes species mosquito. Therefore, the same environmental factors may not drive transmission of both equally. Do the authors have any data on, for example, dengue cases that were reported at the same hospital during the study period?
4. The data are from a country that is at "medium risk for a Zika outbreak". I believe it is more important to know what the estimated seroprevalence of Zika exposure is in this country. This suggests that perhaps Zika is not endemic in the country.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Referee Expertise: Virology, medical entomology, evolution and transmission dynamics of arthropod-borne pathogens

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Jul 2018

Helen Piontkivska, Kent State University

>>> 1. I understand the need for security and thus not naming the hospital but would naming the country truly jeopardize security?

We agree with you in principle; however, the Committee on Administration of the hospital required us not to name the hospital or the country. We added a statement clarifying this.

>>> 2. While I agree that it is possible that African ZIKV has always had the capability of causing CZS and that it is likely underreported or unrecognized, an alternative explanation is that in Africa where ZIKV is endemic girls and women are exposed early in life and subsequent immunity provides protection against CZS during child bearing years. Is there any age distribution that can be associated with the outcomes presented here?

We agree with the reviewer that the question of whether early exposure to ZIKV and/or other flaviviruses may offer subsequent long-term protection against CZS during childbearing years warrants further attention. CZS-type defects analyzed in our study were found in women of ages 15-37 years old; the average number of cases per maternal age class is 2.39 (\pm standard error of 0.42). Thus, these data are not well suited to test this hypothesis, which we hope can be tested in the future with appropriate power.

>>> 3. Throughout comparisons are made to Malaria which is transmitted by Anopheles mosquitoes, whereas, ZIKV is likely transmitted by an Aedes species mosquito. Therefore, the same environmental factors may not drive transmission of both equally. Do the authors have any data on, for example, dengue cases that were reported at the same hospital during the study period?

There are no data on dengue cases available from the hospital. However, the temperature ranges of the peak transmission of malaria and dengue are overlapping [mid 20's °C for malaria, per (Beck-Johnson et al. 2013); 23-34°C for DENV, per (Mordecai et al. 2017)]. Therefore, we expect that the transmission patterns would be similar.

Beck-Johnson, L. M., et al. (2013). "The effect of temperature on Anopheles mosquito population dynamics and the potential for malaria transmission." *PLoS One* 8(11): e79276.

Mordecai, E. A., et al. (2017). "Detecting the impact of temperature on transmission of Zika, dengue, and chikungunya using mechanistic models." *PLoS Negl Trop Dis* 11(4): e0005568.

>>> 4. *The data are from a country that is at "medium risk for a Zika outbreak". I believe it is more important to know what the estimated seroprevalence of Zika exposure is in this country. This suggests that perhaps Zika is not endemic in the country.*

Unfortunately, there are relatively scant data available from the region, most of which comes from the decades-old studies. Specifically, antibodies to ZIKV were found in human blood samples collected in 1960-ies in Senegal, Burkina Faso, Cote D'Ivoire, Guinea-Bissau, Cameroon, Mali, Niger, Benin, Gabon (Brès 1970), in Senegal (Renaudet et al. 1978) and Nigeria (Adekolu-John and Fagbami 1983) in 1970-ies and 1980-ies, supporting the premise that ZIKV is present across multiple countries in West Africa region (reviewed in (Kindhauser et al. 2016)). We hope that this study will motivate the collection of such data in the future. We added these references to the manuscript, to the "Can we expect to find cases of congenital Zika syndrome in the African Continent?" section.

Adekolu-John, E. O. and A. H. Fagbami (1983). "Arthropod-borne virus antibodies in sera of residents of Kainji Lake Basin, Nigeria 1980." *Trans R Soc Trop Med Hyg* 77(2): 149-151.

Brès, P. (1970). "Données récentes apportées par les enquêtes sérologiques sur la prévalence des arbovirus en Afrique, avec référence spéciale à la fièvre jaune [Recent data from serological surveys on the prevalence of arbovirus infections in Africa, with special reference to yellow fever]." *Bulletin of the World Health Organization* 43(2): 223-267.

Kindhauser, M. K., et al. (2016). "Zika: the origin and spread of a mosquito-borne virus." *Bull World Health Organ* 171082.

Renaudet, J., et al. (1978). "[A serological survey of arboviruses in the human population of Senegal]." *Bull Soc Pathol Exot Filiales* 71(2): 131-140.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research